[DE] NEUE 2-SUBSTITUIERTE D-HOMO ESTRA-1,3,5(10)-TRIENE ALS INHIBITOREN DER 17ß-HYDROXYSTEROIDDEHYDROGENASE TYP 1 [EN] NOVEL 2-SUBSTITUTED D-HOMO-ESTRA-1,3,5(10)-TRIENES AS INHIBITORS OF 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 [FR] NOUVEAUX D-HOMO-ESTRA-1,3,5(10)-TRIENES 2-SUBSTITUES SERVANT D'INHIBITEURS DE LA 17ß-HYDROXYSTEROIDE-DESHYDROGENASE DE TYPE 1
[DE] NEUE 2-SUBSTITUIERTE D-HOMO ESTRA-1,3,5(10)-TRIENE ALS INHIBITOREN DER 17ß-HYDROXYSTEROIDDEHYDROGENASE TYP 1 [EN] NOVEL 2-SUBSTITUTED D-HOMO-ESTRA-1,3,5(10)-TRIENES AS INHIBITORS OF 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 [FR] NOUVEAUX D-HOMO-ESTRA-1,3,5(10)-TRIENES 2-SUBSTITUES SERVANT D'INHIBITEURS DE LA 17ß-HYDROXYSTEROIDE-DESHYDROGENASE DE TYPE 1
Structure-based design, synthesis and in vitro characterization of potent 17β-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone
In search for specific drugs against steroid-dependent cancers we have developed a novel set of potent inhibitors of steroidogenic human 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta-HSD 1). The X-ray structure of 17 beta-HSD 1 in complex with estradiol served as basis for the design of the inhibitors. 2-Substituted estrone and D-homo-estrone derivatives were synthesized and tested for 17 beta-HSD 1 inhibition. The best 17 beta-HSD 1 inhibitor, 2-phenethyl-D-homo-estrone, revealed an IC50 of 15 nM in vitro. The inhibitory potency of compounds is comparable or better to that of previously described inhibitors. An interaction within the cofactor binding site is not necessary to obtain this high binding affinity for substances developed. (C) 2009 Elsevier Ltd. All rights reserved.